[1] 卫生部.卫生部办公厅关于抗菌药物临床应用管理有关问题的通知(卫办医政发[2009]38号)[S],中华人民共和国卫生部公报,2009,6:43-45. [2] 张士勇,叶云,程军,等. 预防Ⅰ类切口感染用药的干预对比研究[J].淮海医药,2013,31(2):95-97. [3] 程军,张士勇,叶云.2010-2012年我院抗菌药使用强度调查[J].药物流行病学杂志,2013,22(11):609-611. [4] 于莹,何晓静,张智洁,等.2007-2010年左氧氟沙星用药频度与细菌耐药相关性分析[J].中华医院感染学杂志,2013,23(7):1681-1682. [5] 王金彩,郑继海,杨海楠,等.左氧氟沙星的使用频度与常见细菌耐药相关性分析[J].中国医院药学杂志,2013,3(12):1010-1011. [6] 吴小玲,章志红.2002-2011年临床常见革兰阴性茵对氟喹诺酮类药物耐药趋势文献分析[J].中国全科医学,2013,16(8A):2644-2646. [7] Hsueh P R, Chen W H, Luh K T. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan[J]. Int J Antimicrob Agents,2005,26(6):463-472. [8] MacDougall C, Powell J P, Johnson C K, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals[J]. Clin Infect Dis ,2005,41(4):435-440. [9] Goldmann D A, Huskins W C. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide[J]. Clin Infect Dis,1997,24(Suppl1):S139-145. [10] White R L, Friedrich L V, Mihm L B, et al. Assessment of the relationship between antimicrobial usage and susceptibility: differen-ces between the hospital and specific patient-care areas[J]. Clin Infect Dis ,2000,31(1):16-23. [11] Ray G T, Baxter R, DeLorenze G N. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa[J]. Clin Infect Dis,2005,41(4):441-449. |